Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Historic Convertible Debt for Theravance Biopharma (TBPH) over the last 7 years, with Q2 2022 value amounting to $228.6 million.

  • Theravance Biopharma's Convertible Debt rose 47.12% to $228.6 million in Q2 2022 from the same period last year, while for Jun 2022 it was $228.6 million, marking a year-over-year increase of 47.12%. This contributed to the annual value of $228.0 million for FY2021, which is 47.23% up from last year.
  • Theravance Biopharma's Convertible Debt amounted to $228.6 million in Q2 2022, which was up 47.12% from $228.3 million recorded in Q1 2022.
  • Over the past 5 years, Theravance Biopharma's Convertible Debt peaked at $228.6 million during Q2 2022, and registered a low of $224.0 million during Q1 2018.
  • Over the past 5 years, Theravance Biopharma's median Convertible Debt value was $226.3 million (recorded in 2020), while the average stood at $226.3 million.
  • Per our database at Business Quant, Theravance Biopharma's Convertible Debt skyrocketed by 48.08% in 2018 and then skyrocketed by 47.12% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Convertible Debt stood at $224.8 million in 2018, then rose by 0.48% to $225.9 million in 2019, then grew by 0.48% to $227.0 million in 2020, then increased by 0.47% to $228.0 million in 2021, then rose by 0.24% to $228.6 million in 2022.
  • Its Convertible Debt was $228.6 million in Q2 2022, compared to $228.3 million in Q1 2022 and $228.0 million in Q4 2021.